title: Antibody prophylaxis and therapy against West Nile virus infection in wild-type and immunodeficient mice.
abstract: West Nile virus (WNV) is a mosquito-borne Flavivirus that causes encephalitis in a subset of susceptible humans. Current treatment for WNV infections is supportive, and no specific therapy or vaccine is available. In this study, we directly tested the prophylactic and therapeutic efficacy of polyclonal antibodies against WNV. Passive administration of human gamma globulin or mouse serum prior to WNV infection protected congenic wild-type, B-cell-deficient ( micro MT), and T- and B-cell-deficient (RAG1) C57BL/6J mice. Notably, no increased mortality due to immune enhancement was observed. Although immune antibody completely prevented morbidity and mortality in wild-type mice, its effect was not durable in immunocompromised mice: many micro MT and RAG1 mice eventually succumbed to infection. Thus, antibody by itself did not completely eliminate viral reservoirs in host tissues, consistent with an intact cellular immune response being required for viral clearance. In therapeutic postexposure studies, human gamma globulin partially protected against WNV-induced mortality. In micro MT mice, therapy had to be initiated within 2 days of infection to gain a survival benefit, whereas in the wild-type mice, therapy even 5 days after infection reduced mortality. This time point is significant because between days 4 and 5, WNV was detected in the brains of infected mice. Thus, passive transfer of immune antibody improves clinical outcome even after WNV has disseminated into the central nervous system.
authors.affiliation: Departments of Medicine, Washington University School of Medicine, St. Louis, Missouri 63110, USA.
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Engle
authors.forename: Michael S
authors.initials: MS
authors.lastname: Diamond
mesh_terms: D000818:Animals; D000914:Antibodies, Viral / Q000276:immunology / Q000627:therapeutic use*; D001402:B-Lymphocytes / Q000276:immunology; D004195:Disease Models, Animal; D006801:Humans; D007106:Immune Sera / Q000008:administration & dosage* / Q000276:immunology; D007116:Immunization, Passive; D007121:Immunocompetence; D016867:Immunocompromised Host; D007263:Infusions, Parenteral; D051379:Mice; D020297:Mice, Congenic; D008807:Mice, Inbred BALB C; D013601:T-Lymphocytes / Q000276:immunology; D016896:Treatment Outcome; D014901:West Nile Fever / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality / Q000517:prevention & control*; D014902:West Nile virus / Q000276:immunology
chemical_list: D000914:Antibodies, Viral; D007106:Immune Sera